The Identification of Indacaterol As an Ultralong-Acting Inhaled Beta(2)-Adrenoceptor Agonist
Francois Baur,David Beattie,David Beer,David Bentley,Michelle Bradley,Ian Bruce,Steven J. Charlton,Bernard Cuenoud,Roland Ernst,Robin A. Fairhurst,Bernard Faller,David Farr,Thomas Keller,John R. Fozard,Joe Fullerton,Sheila Garman,Julia Hatto,Claire Hayden,Handan He,Colin Howes,Diana Janus,Zhengjin Jiang,Christine Lewis,Frederique Loeuillet-Ritzler,Heinz Moser,John Reilly,Alan Steward,David Sykes,Lauren Tedaldi,Alexandre Trifilieff,Morris Tweed,Simon Watson,Elke Wissler,Daniel Wyss
DOI: https://doi.org/10.1021/jm100068m
IF: 8.039
2010-01-01
Journal of Medicinal Chemistry
Abstract:Following a lipophilicity-based hypothesis, an 8-hydroxyquinolinone 2-aminoindan derived series of beta(2)-adrenoceptor agonists have been prepared and evaluated for their potential as inhaled ultralong-acting bronchodilators. Determination of their activities at the human beta(2)-adrenoceptor receptor showed symmetrical substitution of the 2-aminoindan moiety at the 5- and 6-positions delivered the targeted intermediate potency and intrinsic-efficacy profiles relative to a series of clinical reference beta(2)-adrenoceptor agonists. Further assessment with an in vitro superfused electrically stimulated guinea-pig tracheal-strip assay established the onset and duration of action time courses, which could be rationalized by considering the lipophilicity, potency, and intrinsic efficacy of the compounds. From these studies the 5,6-diethylindan analogue indacaterol 1c was shown to possess a unique profile of combining a rapid onset of action with a long duration of action. Further in vivo profiling of 1c supported the long duration of action and a wide therapeutic index following administration to the lung, which led to the compound being selected as a development candidate.